These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 24338277)

  • 1. Activity of the hypoxia-activated pro-drug TH-302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy.
    Saggar JK; Tannock IF
    Int J Cancer; 2014 Jun; 134(11):2726-34. PubMed ID: 24338277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in nasopharyngeal carcinoma in vitro and in vivo.
    Huang Y; Tian Y; Zhao Y; Xue C; Zhan J; Liu L; He X; Zhang L
    Cancer Commun (Lond); 2018 May; 38(1):15. PubMed ID: 29764490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer.
    Sun JD; Liu Q; Wang J; Ahluwalia D; Ferraro D; Wang Y; Duan JX; Ammons WS; Curd JG; Matteucci MD; Hart CP
    Clin Cancer Res; 2012 Feb; 18(3):758-70. PubMed ID: 22184053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxia-activated selectivity-improved anti-PKM2 antibody combined with prodrug TH-302 for potentiated targeting therapy in hepatocellular carcinoma.
    Wang B; Qi FZ; Chen P; Qian LM; Su HS; Wang Y; Wang CH; Hou YX; Zhang Q; Li D; Chen ZS; Zhang SH
    Int J Biol Sci; 2024; 20(5):1634-1651. PubMed ID: 38481819
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of pantoprazole to enhance activity of docetaxel against human tumour xenografts by inhibiting autophagy.
    Tan Q; Joshua AM; Saggar JK; Yu M; Wang M; Kanga N; Zhang JY; Chen X; Wouters BG; Tannock IF
    Br J Cancer; 2015 Mar; 112(5):832-40. PubMed ID: 25647012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The hypoxia-activated prodrug evofosfamide in combination with multiple regimens of radiotherapy.
    Nytko KJ; Grgic I; Bender S; Ott J; Guckenberger M; Riesterer O; Pruschy M
    Oncotarget; 2017 Apr; 8(14):23702-23712. PubMed ID: 28423594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrophage delivery of an oncolytic virus abolishes tumor regrowth and metastasis after chemotherapy or irradiation.
    Muthana M; Rodrigues S; Chen YY; Welford A; Hughes R; Tazzyman S; Essand M; Morrow F; Lewis CE
    Cancer Res; 2013 Jan; 73(2):490-5. PubMed ID: 23172310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunofluorescence-Based Method to Assess Cancer Biomarker in the Hypoxic Region of the Tumor.
    Rios-Colon L; Kim S; Su Y; Kumar D; Deep G
    Methods Mol Biol; 2022; 2413():37-43. PubMed ID: 35044652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells.
    Laakkonen P; Akerman ME; Biliran H; Yang M; Ferrer F; Karpanen T; Hoffman RM; Ruoslahti E
    Proc Natl Acad Sci U S A; 2004 Jun; 101(25):9381-6. PubMed ID: 15197262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design of optimized hypoxia-activated prodrugs using pharmacokinetic/pharmacodynamic modeling.
    Foehrenbacher A; Secomb TW; Wilson WR; Hicks KO
    Front Oncol; 2013 Dec; 3():314. PubMed ID: 24409417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor hypoxia: a target for selective cancer therapy.
    Kizaka-Kondoh S; Inoue M; Harada H; Hiraoka M
    Cancer Sci; 2003 Dec; 94(12):1021-8. PubMed ID: 14662015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiation-induced prodrug activation: extending combined modality therapy for some solid tumours.
    Farrer NJ; Higgins GS; Kunkler IH
    Br J Cancer; 2022 May; 126(9):1241-1243. PubMed ID: 35217798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoxia-Activated Theragnostic Prodrugs (HATPs): Current State and Future Perspectives.
    Bhuniya S; Vrettos EI
    Pharmaceutics; 2024 Apr; 16(4):. PubMed ID: 38675218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correction: Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer.
    Sun JD; Liu Q; Wang J; Ahluwalia D; Ferraro D; Wang Y; Duan JX; Ammons WS; Curd JG; Matteucci MD; Hart CP
    Clin Cancer Res; 2024 May; 30(10):2287. PubMed ID: 38745478
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma.
    Chawla SP; Cranmer LD; Van Tine BA; Reed DR; Okuno SH; Butrynski JE; Adkins DR; Hendifar AE; Kroll S; Ganjoo KN
    J Clin Oncol; 2014 Oct; 32(29):3299-306. PubMed ID: 25185097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pyruvate induces transient tumor hypoxia by enhancing mitochondrial oxygen consumption and potentiates the anti-tumor effect of a hypoxia-activated prodrug TH-302.
    Takakusagi Y; Matsumoto S; Saito K; Matsuo M; Kishimoto S; Wojtkowiak JW; DeGraff W; Kesarwala AH; Choudhuri R; Devasahayam N; Subramanian S; Munasinghe JP; Gillies RJ; Mitchell JB; Hart CP; Krishna MC
    PLoS One; 2014; 9(9):e107995. PubMed ID: 25254649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy Rescues Hypoxic Tumor Cells and Induces Their Reoxygenation and Repopulation-An Effect That Is Inhibited by the Hypoxia-Activated Prodrug TH-302.
    Saggar JK; Tannock IF
    Clin Cancer Res; 2015 May; 21(9):2107-14. PubMed ID: 25677696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the "steal" phenomenon on the efficacy of hypoxia activated prodrug TH-302 in pancreatic cancer.
    Bailey KM; Cornnell HH; Ibrahim-Hashim A; Wojtkowiak JW; Hart CP; Zhang X; Leos R; Martinez GV; Baker AF; Gillies RJ
    PLoS One; 2014; 9(12):e113586. PubMed ID: 25532146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyruvate sensitizes pancreatic tumors to hypoxia-activated prodrug TH-302.
    Wojtkowiak JW; Cornnell HC; Matsumoto S; Saito K; Takakusagi Y; Dutta P; Kim M; Zhang X; Leos R; Bailey KM; Martinez G; Lloyd MC; Weber C; Mitchell JB; Lynch RM; Baker AF; Gatenby RA; Rejniak KA; Hart C; Krishna MC; Gillies RJ
    Cancer Metab; 2015; 3(1):2. PubMed ID: 25635223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxia-activated pro-drug TH-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcoma.
    Liapis V; Labrinidis A; Zinonos I; Hay S; Ponomarev V; Panagopoulos V; DeNichilo M; Ingman W; Atkins GJ; Findlay DM; Zannettino ACW; Evdokiou A
    Cancer Lett; 2015 Feb; 357(1):160-169. PubMed ID: 25444931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.